Open | - |
Close | - |
Volume / Avg. | 0 / 2.300M |
Day Range | - - - |
52 Wk Range | 17.435 - 24.340 |
Market Cap | $7.025B |
P/E Ratio | 35.646 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 65 |
Short Interest | 3.17% |
Days to Cover | 3.7 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Cerevel Therapeutics Hldg (NASDAQ:CERE).
The latest price target for Exelixis (NASDAQ: EXEL) was reported by RBC Capital on Wednesday, February 7, 2024. The analyst firm set a price target for 28.00 expecting EXEL to rise to within 12 months (a possible 20.85% upside). 29 analyst firms have reported ratings in the last year.
The stock price for Exelixis (NASDAQ: EXEL) is $23.17 last updated March 18, 2024 at 4:10 PM EDT.
There are no upcoming dividends for Exelixis.
Exelixis’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.